✦ LIBER ✦

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

✍ Scribed by Jens Samol, Malcolm Ranson, Edwina Scott, Euan Macpherson, James Carmichael, Anne Thomas, James Cassidy

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of the safety and tolera

✍ Khan, O A; Gore, M; Lorigan, P; Stone, J; Greystoke, A; Burke, W; Carmichael, J; 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 329 KB

1257 POSTER Phase I Safety and Tolerabil

✍ C. Sessa; R. von Moos; T. Digena; G. Del Conte; L. Viganö; E. Gallerani; R. Cath 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 63 KB

A Phase 1 trial of the poly(ADP-ribose)

✍ Liu, Joyce F.; Tolaney, Sara M.; Birrer, Michael; Fleming, Gini F.; Buss, Mary K 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 580 KB

A Phase I study to assess the safety, to

✍ J. R. Infante; R. Kurzrock; J. Spratlin; H. A. Burris; S. G. Eckhardt; J. Li; K. 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 338 KB

Phase I trial of olaparib in combination

✍ Balmana, J.; Tung, N. M.; Isakoff, S. J.; Grana, B.; Ryan, P. D.; Saura, C.; Low 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 144 KB

50 A phase I study of the safety, tolera

✍ H. Richly; S.D. Rubin; A. Madi; M. Jeffels; B. Nokay; D. Gibson; S. Weller; M.E. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 44 KB